<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Exploring High Growth Tech Stocks in the US Market September 2025</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Exploring High Growth Tech Stocks in the US Market September 2025</h1>
  <ul>
<li>The company's commitment to shareholder value is evident through its aggressive share repurchase strategy, having bought back 600,000 shares for $10.7 million recently, completing nearly 10% of its announced buyback plan</li>
<li>The company's strategic presence at key healthcare conferences signifies its active engagement in expanding industry influence and investor relations, while revised upward revenue guidance for 2025 between $625 million a</li>
<li>As of September 2025, the U.S.</li>
<li>Notably, Protagonist's revenue is projected to grow at an impressive rate of 22% annually, outpacing the broader US market forecast of 9.6%.</li>
<li>Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $529.33 million.</li>
<li>This performance is underscored by an impressive annualized earnings growth rate of 36.9%, substantially outpacing the broader U.S market's growth rate of 15.4%.</li>
<li>Operations: Protagonist Therapeutics focuses on developing peptide therapeutics, generating revenue primarily from its biotechnology segment, which reported $209.18 million.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-113820579.html">Source</a> · 2025-09-15T11:38:20+00:00</p>
</body>
</html>